AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
JAMA Editors' Summary
Adding Tirzepatide vs Prandial Insulin to Basal Insulin, Beta-Blockers in Septic Shock, USPSTF on Oral Health Screening, and more
Nov 7, 2023
This podcast discusses topics such as the efficacy of Chrysepatide and Insulinless Pro in Type 2 diabetes, the use of Landial Lald in Septic Shock, alcohol use disorder therapies, AI in radiology, sepsis management, drug price negotiations, prevention research, oral health screening, non-alcoholic fatty liver disease management, health equity in AI tools, and climate change's impact on mental health in Africa.
12:19
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Tirzepatide demonstrated better outcomes in Type 2 diabetes compared to Insulinless Pro.
- Oral naltrexone and acamprosate showed promise in treating alcohol use disorder.
Deep dives
Chrysepatide vs. Insulinless Pro in Type 2 Diabetes
A Phase 3 clinical trial compared the efficacy and safety of Chrysepatide and Insulinless Pro as adjunctive therapies to basal insulin in Type 2 diabetes. Chrysepatide showed a statistically significant improvement in hemoglobin A1C levels, less hypoglycemia, and more reduction in body weight compared to Insulinless Pro.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode